Jaakkola Tytti, Merras-Salmio Laura, Nikkonen Anne, Kolho Kaija-Leena
Pediatric Gastroenterology Unit, Children's Hospital, Helsinki University Hospital HUS, Helsinki, Finland.
Faculty of Medicine, University of Helsinki, Helsinki, Finland.
J Pediatr Gastroenterol Nutr. 2025 Jan;80(1):124-132. doi: 10.1002/jpn3.12397. Epub 2024 Nov 1.
We report disease outcomes of pediatric Crohn's disease (CD) affecting the proximal small bowel (SB) and detected through video capsule endoscopy (VCE).
We undertook a retrospective review of CD patients with VCE performed under age 18 between 2003 and 2017 and having received any biologics. We identified patients from our institutional registry.
Eligible patients (n = 118) had their first VCE performed after a median of 0.1 years after diagnostic endoscopies at a median age of 12.2 years. The proximal SB disease group (Paris classification L4b inclusive) comprised 70 patients with extensive SB lesions in 81% and deep ulcers in 79%. Patients with Paris L1-3 disease with no findings in VCE or disease restricted to the terminal ileum comprised the control group. At first VCE, levels of albumin (34 vs. 37 g/L) and hemoglobin (117 vs. 127 g/L) were lower in SB patients (p < 0.02). After the first VCE, 68% were introduced to biologics, while 10% already received them. Follow-up VCE was performed after a median of 2.4 years (SB group n = 42; controls n = 21). Proximal SB findings had disappeared in 40% of SB patients, and extensive lesions and deep ulcers had decreased to 26% and 29%, respectively (p = 0.001). In the control group, one had progressed to proximal disease. During the clinical follow-up of a median of 4.7 years, one patient with SB underwent surgery for a jejunal stricture.
Proximal SB disease detected through capsule endoscopy abated in most patients with biological medication.
我们报告了通过视频胶囊内镜(VCE)检测到的影响近端小肠(SB)的儿童克罗恩病(CD)的疾病转归情况。
我们对2003年至2017年间接受VCE检查且年龄在18岁以下并接受过任何生物制剂治疗的CD患者进行了回顾性研究。我们从机构登记处识别出患者。
符合条件的患者(n = 118)在诊断性内镜检查后中位0.1年进行了首次VCE检查,中位年龄为12.2岁。近端SB疾病组(包括巴黎分类L4b)包括70例患者,其中81%有广泛的SB病变,79%有深部溃疡。VCE检查无异常或疾病仅限于回肠末端的巴黎L1 - 3疾病患者组成对照组。在首次VCE检查时,SB患者的白蛋白水平(34 vs. 37 g/L)和血红蛋白水平(117 vs. 127 g/L)较低(p < 0.02)。首次VCE检查后,68%的患者开始使用生物制剂,而10%的患者已经在使用。中位2.4年后进行了随访VCE检查(SB组n = 42;对照组n = 21)。40%的SB患者近端SB病变消失,广泛病变和深部溃疡分别降至26%和29%(p = 0.001)。在对照组中,有1例进展为近端疾病。在中位4.7年的临床随访期间,1例SB患者因空肠狭窄接受了手术。
通过胶囊内镜检测到的近端SB疾病在大多数接受生物药物治疗的患者中病情缓解。